☰

Anda M. Vlad, Ph.D. - Publications

Affiliations: 
2002 University of Pittsburgh, Pittsburgh, PA, United States 
Area:
Immunology, Oncology, Cell Biology
Tree Info Grants Similar researchers PubMed Report error

53 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Hartnett EG, Knight J, Radolec M, Buckanovich RJ, Edwards RP, Vlad AM. Immunotherapy Advances for Epithelial Ovarian Cancer. Cancers. 12. PMID 33322601 DOI: 10.3390/cancers12123733  0.348
2019 Bai S, Zhu W, Coffman L, Vlad A, Schwartz LE, Elishaev E, Drapkin R, Buckanovich RJ. CD105 Is Expressed in Ovarian Cancer Precursor Lesions and Is Required for Metastasis to the Ovary. Cancers. 11. PMID 31684072 DOI: 10.3390/Cancers11111710  0.343
2018 Grabosch S, Bulatovic M, Zeng F, Ma T, Zhang L, Ross M, Brozick J, Fang Y, Tseng G, Kim E, Gambotto A, Elishaev E, P Edwards R, Vlad AM. Cisplatin-induced immune modulation in ovarian cancer mouse models with distinct inflammation profiles. Oncogene. PMID 30518877 DOI: 10.1038/S41388-018-0581-9  0.44
2018 Qin Y, Vasilatos SN, Chen L, Wu H, Cao Z, Fu Y, Huang M, Vlad AM, Lu B, Oesterreich S, Davidson NE, Huang Y. Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade. Oncogene. PMID 30111819 DOI: 10.1038/S41388-018-0451-5  0.413
2018 Ross MS, Tianzhou M, Zhang L, Priedigkeit N, Tseng G, Lee AV, Edwards RP, Vlad AM. Abstract B33: Neoepitope peptide vaccines and immune checkpoint blockade in a new preclinical ovarian cancer model Clinical Cancer Research. 24. DOI: 10.1158/1557-3265.Ovca17-B33  0.406
2018 Grabosch S, Bulatovic M, Zeng F, Ma T, Zhang L, Ross M, Brozick J, Tseng G, Elishaev E, Edwards RP, Vlad A. Abstract B29: Cisplatin is pro-immunogenic and promotes intrinsic and reactive immune suppression in inflamed and noninflamed ovarian cancer mouse models Clinical Cancer Research. 24. DOI: 10.1158/1557-3265.Ovca17-B29  0.412
2018 Boisen M, Andersen C, Sikora M, Ma T, Tseng G, Vlad A, Elishaev E, Chandran U, Edwards R, Oesterreich S. Abstract B23: The evolution of estrogen receptor signaling in the progression of endometriosis to endometriosis-associated ovarian cancer Clinical Cancer Research. 24. DOI: 10.1158/1557-3265.Ovca17-B23  0.318
2018 Ross M, Tianzhou M, Zhang L, Tseng G, Edwards R, Vlad A. Immune checkpoint blockade and a neoepitope vaccine in a metastatic ovarian cancer model Gynecologic Oncology. 149: 83-84. DOI: 10.1016/J.Ygyno.2018.04.191  0.335
2018 Ross M, Tianzhou M, Priedigkeit N, Zhang L, Tseng G, Lee A, Edwards R, Vlad A. An in vitro evaluation of neoantigens derived from gene fusion events in ovarian cancer patients Gynecologic Oncology. 149: 8. DOI: 10.1016/J.Ygyno.2018.04.025  0.313
2017 Budiu RA, Vlad AM, Nazario L, Bathula C, Cooper KL, Edmed J, Thaker PH, Urban J, Kalinski P, Lee AV, Elishaev EL, Conrads TP, Flint MS. Restraint and Social Isolation Stressors Differentially Regulate Adaptive Immunity and Tumor Angiogenesis in a Breast Cancer Mouse Model. Cancer and Clinical Oncology. 6: 12-24. PMID 28603578 DOI: 10.5539/Cco.V6N1P12  0.354
2017 Grabosch S, Tseng G, Edwards RP, Lankes HA, Moore K, Odunsi K, Vlad A, Ma T, Strange M, Brozick J, Lugade A, Omilian A, Bshara W, Stuckey AR, Walker JL, et al. Multiplex profiling identifies distinct local and systemic alterations during intraperitoneal chemotherapy for ovarian cancer: An NRG Oncology/Gynecologic Oncology Group Study. Gynecologic Oncology. PMID 28483269 DOI: 10.1016/J.Ygyno.2017.04.008  0.398
2017 Cascio S, Faylo J, Sriram R, Vlad A, Camacho C, Finn OJ. Abstract 4126: Validation of hypoglycosylated MUC1-CIN85 protein-protein interaction as a new therapeutic target for prevention of cancer invasion and metastasis Cancer Research. 77: 4126-4126. DOI: 10.1158/1538-7445.Am2017-4126  0.595
2017 Grabosch S, Zeng F, Ma T, Zhang L, Guido E, Tseng G, Edwards R, Vlad A, Brozick J. Novel combination immunotherapy with MUC1 vaccination and immune checkpoint blockade in ovarian cancer Gynecologic Oncology. 145: 86. DOI: 10.1016/J.Ygyno.2017.03.202  0.342
2016 Zhang L, Ma T, Brozick J, Babalola K, Budiu R, Tseng G, Vlad AM. Effects of Kras activation and Pten deletion alone or in combination on MUC1 biology and epithelial-to-mesenchymal transition in ovarian cancer. Oncogene. PMID 26973247 DOI: 10.1038/Onc.2016.53  0.321
2016 Grabosch S, Zeng F, Zhang L, Strange M, Brozick J, Edwards RP, Vlad A. Abstract A59: PD-L1 biology in response to chemotherapy in vitro and in vivo in ovarian cancer. Clinical Cancer Research. 22. DOI: 10.1158/1557-3265.Ovca15-A59  0.327
2016 Grabosch S, Zeng F, Zhang L, Ma T, Tseng G, Edwards RP, Vlad AM. Abstract 3208: Chemo-induced biology of PD-L1 andin vivocombination immune therapy for ovarian cancer Cancer Research. 76: 3208-3208. DOI: 10.1158/1538-7445.Am2016-3208  0.372
2016 Boisen M, Andersen C, Sikora M, Ma T, Tseng G, Vlad A, Elishaev E, Chandran U, Edwards R, Oesterreich S. The evolution of estrogen receptor signaling in the progression of endometriosis to endometriosis-associated ovarian cancer Gynecologic Oncology. 141: 113-114. DOI: 10.1016/J.Ygyno.2016.04.305  0.309
2016 Grabosch S, Zeng F, Ma T, Zhang L, Brozick J, Tseng G, Edwards R, Vlad A. Chemo-induced biology of PD-L1 and in vivo combination immune therapy for ovarian cancer Gynecologic Oncology. 141: 86. DOI: 10.1016/J.Ygyno.2016.04.239  0.328
2015 Edwards RP, Huang X, Vlad AM. Chronic inflammation in endometriosis and endometriosis-associated ovarian cancer: New roles for the "old" complement pathway. Oncoimmunology. 4: e1002732. PMID 26155393 DOI: 10.1080/2162402X.2014.1002732  0.373
2015 Mony JT, Zhang L, Ma T, Grabosch S, Tirodkar TS, Brozick J, Tseng G, Elishaev E, Edwards RP, Huang X, Vlad AM. Anti-PD-L1 prolongs survival and triggers T cell but not humoral anti-tumor immune responses in a human MUC1-expressing preclinical ovarian cancer model. Cancer Immunology, Immunotherapy : Cii. PMID 25998800 DOI: 10.1007/S00262-015-1712-6  0.432
2015 Grabosch S, Zeng F, Zhang L, Strange M, Brozick J, Edwards RP, Vlad A. PD-L1 biology in response to chemotherapy in vitro and in vivo in ovarian cancer Journal For Immunotherapy of Cancer. 3. DOI: 10.1186/2051-1426-3-S2-P302  0.3
2015 Mony J, Zhang L, Tirodkar T, Elishaev E, Brozick J, Edwards RP, Vlad AM. Abstract POSTER-THER-1434: Intraperitoneal anti-PD-L1 increases survival in a novel ovarian cancer model and its in vivo efficacy is influenced by baseline anti-tumor immunity of the host Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Ovcasymp14-Poster-Ther-1434  0.414
2015 Grabosch S, Vlad AM, Ma T, Mony JT, Strange M, Brozick J, Thaller J, Tseng G, Huang X, Moore K, Odunsi K, Edwards RP. Abstract 414: Prospective profiling of systemic and loco-regional alterations during intraperitoneal chemotherapy for ovarian cancer, results from GOG 271 Cancer Research. 75: 414-414. DOI: 10.1158/1538-7445.Am2015-414  0.307
2015 Zhang L, Ma T, Brozick J, Babalola K, Budiu R, Tseng G, Vlad A. Abstract 4081: Lung metastasis of ovarian cancer in a transplantable MUC1.Tg mouse model is accompanied by upregulation of MUC1 expression and epithelial to mesenchymal transition Cancer Research. 75: 4081-4081. DOI: 10.1158/1538-7445.Am2015-4081  0.393
2015 Grabosch S, Mony JT, Zhang L, Ma T, Tirodkar T, Brozick J, Tseng G, Elishaev E, Edwards RP, Huang X, Vlad AM. Abstract 260: In vivo efficacy of intraperitoneal anti-PD-L1 therapy in ovarian cancer Cancer Research. 75: 260-260. DOI: 10.1158/1538-7445.Am2015-260  0.401
2015 Berger J, Beck T, Mital P, Elishaev E, Sukhwani M, Oesterreich S, Vlad A, Krivak T, Kelley J, Orwig K. A novel orthotopic mouse model of epithelial ovarian carcinoma demonstrating progression from early stage disease to carcinomatosis in both immune-competent and immune-deficient models Gynecologic Oncology. 137: 132. DOI: 10.1016/J.Ygyno.2015.01.329  0.301
2014 Suryawanshi S, Huang X, Elishaev E, Budiu RA, Zhang L, Kim S, Donnellan N, Mantia-Smaldone G, Ma T, Tseng G, Lee T, Mansuria S, Edwards RP, Vlad AM. Complement pathway is frequently altered in endometriosis and endometriosis-associated ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 6163-74. PMID 25294912 DOI: 10.1158/1078-0432.Ccr-14-1338  0.412
2014 Tirodkar TS, Budiu RA, Elishaev E, Zhang L, Mony JT, Brozick J, Edwards RP, Vlad AM. MUC1 positive, Kras and Pten driven mouse gynecologic tumors replicate human tumors and vary in survival and nuclear grade based on anatomical location. Plos One. 9: e102409. PMID 25078979 DOI: 10.1371/Journal.Pone.0102409  0.381
2014 Zhang L, Budiu R, Brozick J, Vlad AM. Abstract 4976: Novel ovarian cancer transplantable models generated from MUC1KrasPten tumors show in vitro and in vivo heterogeneity Cancer Research. 74: 4976-4976. DOI: 10.1158/1538-7445.Am2014-4976  0.412
2014 Suryawanshi SM, Huang X, Budiu R, Kim S, Tseng G, Elishaev E, Klein-Patel M, Lee T, Mansuria S, Edwards R, Vlad A. Abstract 1653: Complement roles in endometriosis and endometriosis-associated ovarian cancer Cancer Research. 74: 1653-1653. DOI: 10.1158/1538-7445.Am2014-1653  0.4
2013 Oesterreich S, Edwards R, Vlad A. Progestins: pro-senescence therapy for ovarian cancer? Cell Cycle (Georgetown, Tex.). 12: 1662-3. PMID 23708445 DOI: 10.4161/Cc.25072  0.444
2013 Suryawanshi S, Vlad AM, Lin HM, Mantia-Smaldone G, Laskey R, Lee M, Lin Y, Donnellan N, Klein-Patel M, Lee T, Mansuria S, Elishaev E, Budiu R, Edwards RP, Huang X. Plasma microRNAs as novel biomarkers for endometriosis and endometriosis-associated ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 1213-24. PMID 23362326 DOI: 10.1158/1078-0432.Ccr-12-2726  0.333
2013 Budiu RA, Elishaev E, Brozick J, Lee M, Edwards RP, Kalinski P, Vlad AM. Immunobiology of human mucin 1 in a preclinical ovarian tumor model. Oncogene. 32: 3664-75. PMID 22964632 DOI: 10.1038/Onc.2012.397  0.438
2013 Zhang L, Vlad A, Milcarek C, Finn OJ. Human mucin MUC1 RNA undergoes different types of alternative splicing resulting in multiple isoforms. Cancer Immunology, Immunotherapy : Cii. 62: 423-35. PMID 22941036 DOI: 10.1007/S00262-012-1325-2  0.545
2013 Suryawanshi S, Huang X, Budiu R, Mantia G, Edwards R, Vlad A. Abstract B71: Immune mechanisms that drive early carcinogenesis in endometriosis-associated ovarian cancer Clinical Cancer Research. 19. DOI: 10.1158/1078-0432.Ovca13-B71  0.401
2013 Zhang L, Budiu R, Brozick J, Vlad A. Abstract B66: Novel ovarian cancer transplantable models generated from MUC1KrasPten tumors show different in vitro and in vivo biological behaviors Clinical Cancer Research. 19. DOI: 10.1158/1078-0432.Ovca13-B66  0.432
2013 Budiu R, Vlad A, Nazario L, Bathula C, Cooper K, Esther E, Flint M. 97. Impact of psychological stress on the adaptive immune system and disease progression in a triple negative breast and a transgenic ovarian cancer mouse model Brain, Behavior, and Immunity. 32: e28. DOI: 10.1016/J.Bbi.2013.07.109  0.354
2012 Suryawanshi SM, Edwards R, Vlad A, Huang X. Abstract LB-479: Plasma microRNAs as novel biomarkers for endometriosis and endometriosis associates ovarian cancer Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Lb-479  0.3
2011 Mantia-Smaldone GM, Edwards RP, Vlad AM. Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies. Cancer Management and Research. 3: 25-38. PMID 21734812 DOI: 10.2147/Cmr.S8759  0.363
2011 Budiu RA, Mantia-Smaldone G, Elishaev E, Chu T, Thaller J, McCabe K, Lenzner D, Edwards RP, Vlad AM. Soluble MUC1 and serum MUC1-specific antibodies are potential prognostic biomarkers for platinum-resistant ovarian cancer. Cancer Immunology, Immunotherapy : Cii. 60: 975-84. PMID 21461842 DOI: 10.1007/S00262-011-1010-X  0.37
2011 Budiu RA, Elishaev E, Brozick J, Chu T, Predoiu S, Edwards RP, Vlad AM. Abstract 751: Vaccination with MUC1-pulsed dendritic cells prolongs survival in triple transgenic mice with orthotopic ovarian tumors Cancer Research. 71: 751-751. DOI: 10.1158/1538-7445.Am2011-751  0.387
2011 Flint MS, Budiu RA, Conrads TP, Vlad AM. Abstract 1835: Mechanisms of psychological stress on the adaptive immune system and disease progression in a novel double transgenic ovarian cancer mouse model Cancer Research. 71: 1835-1835. DOI: 10.1158/1538-7445.Am2011-1835  0.366
2010 Vlad AM, Budiu RA, Lenzner DE, Wang Y, Thaller JA, Colonello K, Crowley-Nowick PA, Kelley JL, Price FV, Edwards RP. A phase II trial of intraperitoneal interleukin-2 in patients with platinum-resistant or platinum-refractory ovarian cancer. Cancer Immunology, Immunotherapy : Cii. 59: 293-301. PMID 19690855 DOI: 10.1007/S00262-009-0750-3  0.361
2010 Budiu RA, Mantia-Smaldone GM, Brozick J, Edwards RP, Vlad AM. Abstract 4793: MUC1 immunogenicity in a triple transgenic mouse model for epithelial ovarian cancer Cancer Research. 70: 4793-4793. DOI: 10.1158/1538-7445.Am10-4793  0.454
2010 Mantia-Smaldone GM, Budiu R, Mansuria S, Lee T, Zorn K, Elishaev E, Edwards RP, Vlad A. Abstract 1335: Immune regulation in endometriosis and epithelial ovarian cancer Cancer Research. 70: 1335-1335. DOI: 10.1158/1538-7445.Am10-1335  0.361
2009 Budiu RA, Diaconu I, Chrissluis R, Dricu A, Edwards RP, Vlad AM. A conditional mouse model for human MUC1-positive endometriosis shows the presence of anti-MUC1 antibodies and Foxp3+ regulatory T cells. Disease Models & Mechanisms. 2: 593-603. PMID 19841240 DOI: 10.1242/Dmm.002535  0.384
2009 Ryan SO, Vlad AM, Islam K, Gariépy J, Finn OJ. Tumor-associated MUC1 glycopeptide epitopes are not subject to self-tolerance and improve responses to MUC1 peptide epitopes in MUC1 transgenic mice Biological Chemistry. 390: 611-618. PMID 19426130 DOI: 10.1515/Bc.2009.070  0.576
2006 Vlad AM, Diaconu I, Gantt KR. MUC1 in endometriosis and ovarian cancer. Immunologic Research. 36: 229-36. PMID 17337783 DOI: 10.1385/Ir:36:1:229  0.386
2004 Vlad AM, Finn OJ. Glycoprotein tumor antigens for immunotherapy of breast cancer. Breast Disease. 20: 73-9. PMID 15687709 DOI: 10.3233/Bd-2004-20109  0.599
2004 Vlad AM, Kettel JC, Alajez NM, Carlos CA, Finn OJ. MUC1 immunobiology: from discovery to clinical applications. Advances in Immunology. 82: 249-93. PMID 14975259 DOI: 10.1016/S0065-2776(04)82006-6  0.51
2003 Correa I, Plunkett T, Vlad A, Mungul A, Candelora-Kettel J, Burchell JM, Taylor-Papadimitriou J, Finn OJ. Form and pattern of MUC1 expression on T cells activated in vivo or in vitro suggests a function in T-cell migration. Immunology. 108: 32-41. PMID 12519300 DOI: 10.1046/J.1365-2567.2003.01562.X  0.543
2002 Vlad AM, Muller S, Cudic M, Paulsen H, Otvos L, Hanisch FG, Finn OJ. Complex carbohydrates are not removed during processing of glycoproteins by dendritic cells: processing of tumor antigen MUC1 glycopeptides for presentation to major histocompatibility complex class II-restricted T cells. The Journal of Experimental Medicine. 196: 1435-46. PMID 12461079 DOI: 10.1084/Jem.20020493  0.552
2000 Hiltbold EM, Vlad AM, Ciborowski P, Watkins SC, Finn OJ. The mechanism of unresponsiveness to circulating tumor antigen MUC1 is a block in intracellular sorting and processing by dendritic cells. Journal of Immunology (Baltimore, Md. : 1950). 165: 3730-41. PMID 11034378 DOI: 10.4049/Jimmunol.165.7.3730  0.565
Show low-probability matches.